Abstract:
Dr. Shu will share insights from the trial’s development to its promising outcomes, highlighting the safety and effectiveness of this novel treatment. The session includes an interactive Q&A, providing a deeper understanding of gene therapy’s potential to change lives for those affected by genetic hearing loss.
Ideal for healthcare professionals, researchers, and families impacted by ARD9, this webinar offers a glimpse into the future of hearing loss treatment through the lens of gene therapy.
Time:
Speaker:
Company: Eye & ENT Hospital of Fudan University, Shanghai
Title: Medical Doctor
Biography
Dr. Shu’s scholarly contributions are remarkable, with over 86 SCI papers to his name, including more than 60 as first or corresponding author in globally renowned journals. His groundbreaking work in genetic deafness gene therapy, particularly through collaborative efforts with notable figures such as David Liu and Zheng-Yi Chen, has pioneered new therapeutic avenues. His research achievements have earned him prestigious recognitions, including the National Science Fund for Distinguished Young Scholars. Dr. Shu holds influential positions in key medical and scientific societies, driving forward the discourse in otorhinolaryngology on both national and international stages. His dedication to advancing healthcare through innovation and research underscores his profound impact on the medical community and patient care worldwide.
Related services:
Express Gene to AAV Service
READ MORE
